Primary Sclerosing Cholangitis After Liver Transplant With Oral Vancomycin
A legfontosabb adatok
- Ki végzi
- Yael R. Nobel
- Hol
- New York (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 1. fázis
- Résztvevők
- 21 fő, tervezett
- Kezdés
- 2026. nov.
- Várható befejezés
- 2030. nov.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
- A vizsgált kezelések
- Oral Vancomycin
- A regiszteradat frissítve
- 2026. november 18.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 18 years
- Ability to provide written, informed consent
- History of orthotopic liver transplantation within 1 to 10 years prior to enrollment (i.e. study drug initiation)
- Diagnosis of PSC as the underlying liver disease leading to liver transplantation, based on compatible imaging findings (magnetic resonance cholangiopancreatography [MRCP], endoscopic retrograde cholangiopancreatography [ERCP], percutaneous transhepatic cholangiogram [PTC]), liver histology, and/or clinician judgment
- Subjects with or without IBD may be enrolled. IBD diagnosis with a minimum disease duration of 6 months as assessed by endoscopy/histology. IBD should be in clinical remission or mildly active according to accepted clinical scores and/or clinician judgment
- Stable liver graft function, as determined by ALL of the following criteria:; No episodes of acute rejection within 6 months prior to enrollment, based on liver histology and/or clinical signs or symptoms; No episodes of cholangitis within 6 months prior to study enrollment, based on positive bacterial cultures, compatible imaging, and/or clinical signs or symptoms; No intervention for biliary obstruction (e.g. ERCP, PTC, surgical intervention) within 6 months prior to study enrollment; Stable liver biochemistries within 6 months prior to study enrollment, as determined by: ALP <5x ULN; Absence of histologic or imaging findings suggestive of cirrhosis
Ki nem vehet részt
- History of colon resection at any time prior to study enrollment or presence of ileal/colonic diversion within 12 months prior to study enrollment
- Documented VRE infection within 12 months prior to study enrollment
- Documented C. difficile infection within 3 months prior to study enrollment
- Systemic antibiotic exposure within 3 months prior to study enrollment
- Change in any transplant or IBD-related immunosuppression or its dosing within 30 days prior to study enrollment
- Currently taking oral vancomycin
- Treatment with any investigational drug within 3 months prior to study enrollment
- Allergy or intolerance to vancomycin
- Any active malignancy
- Any condition that, in the investigator's judgment, would make participation unsafe or interfere with adherence (e.g., severe frailty, uncontrolled psychiatric disease, inability to adhere to TID dosing)
- Severe renal dysfunction (eGFR <30 mL/min/1.73 m²) or on dialysis
- Pregnant or breastfeeding Page 8
Helyszínek itt: Egyesült Államok
- Columbia UniversityNew York, Egyesült ÁllamokContact: Rebecca YehToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
Primary Objective:
A teljes eredeti leírásKevesebb
* To evaluate safety of a 4-week course of oral vancomycin (250 mg 3 times daily [TID]) in liver transplant recipients who were transplanted for Primary Sclerosing Cholangitis (PSC).
Secondary Objectives:
* To determine tolerability and adherence to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. * To assess vancomycin resistant enterococcus (VRE) colonization status over time. * To assess the impact of oral vancomycin on stool microbiome composition, diversity, and function. * To assess impact of oral vancomycin on microbial metabolite concentrations in blood and stool. * To assess impact of oral vancomycin on liver-related biochemical markers.
A vizsgálat 2 csoportja
- Study Arm - Oral VancomycinA vizsgált kezelés
Patients in study arm will be assigned to receive study drug.
Kezelés: Oral Vancomycin
- Control Arm - No DrugNincs vizsgálati kezelés, összehasonlításként
Patients in control arm will be assigned to receive no drug.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Preventing Recurrence of Primary Sclerosing Cholangitis After Liver Transplant (PROP-LT): a Phase 1, Open-label, Controlled Study of Oral Vancomycin
- A regiszteradat frissítve
- 2026. november 18.